1. Home
  2. GLW vs SNY Comparison

GLW vs SNY Comparison

Compare GLW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corning Incorporated

GLW

Corning Incorporated

HOLD

Current Price

$177.18

Market Cap

149.7B

Sector

Industrials

ML Signal

HOLD

Logo Sanofi ADS

SNY

Sanofi ADS

HOLD

Current Price

$44.15

Market Cap

104.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLW
SNY
Founded
1851
1994
Country
United States
France
Employees
N/A
74846
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
149.7B
104.5B
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
GLW
SNY
Price
$177.18
$44.15
Analyst Decision
Buy
Buy
Analyst Count
12
5
Target Price
$146.91
$58.00
AVG Volume (30 Days)
10.2M
2.3M
Earning Date
04-28-2026
04-23-2026
Dividend Yield
0.74%
3.47%
EPS Growth
215.52
N/A
EPS
0.43
N/A
Revenue
$15,629,000,000.00
N/A
Revenue This Year
$20.74
$3.49
Revenue Next Year
$12.80
$6.10
P/E Ratio
$391.35
$6.14
Revenue Growth
19.14
N/A
52 Week Low
$49.47
$42.28
52 Week High
$211.79
$52.68

Technical Indicators

Market Signals
Indicator
GLW
SNY
Relative Strength Index (RSI) 47.73 51.69
Support Level $171.11 $42.30
Resistance Level $177.92 $48.76
Average True Range (ATR) 11.93 0.60
MACD -3.11 0.16
Stochastic Oscillator 26.07 75.00

Price Performance

Historical Comparison
GLW
SNY

About GLW Corning Incorporated

Corning is a provider of glass, ceramics, and optical fiber across six distinct end markets. Corning's largest segments by revenue are display glass for TVs and optical fiber for telecom networks and data centers. It also provides cover glass for smartphones as well as filters and substrates and glass for cars, produces pharmaceutical glass, and produces polysilicon for solar panels. Corning is a US producer and is vertically integrated across its products and markets.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: